All News

RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
CAR T on purple background

How many CAR-T’s do we need to test drive?

Janet Pope, MD, MPH, FRCPC

CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.

Read Article
EULAR meeting room

NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK

Henrique Dalmolin, MD

Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.

Read Article
Eular stage

What’s New in Macrophage Activation Syndrome Therapeutics

Bella Mehta, MBBS, MS

MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.

Read Article
green container of pills

New Oral Option for axSpA: Filgotinib for Radiographic and Non-Radiographic Disease

Antoni Chan, MD, PhD

The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?

Read Article
Checklist IgG4

INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease

Henrique Dalmolin, MD

B-cell targeting has moved to the centre of IgG4-related disease treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.

Read Article
lupus.nephritis.immunofluorescence.jpg

Obinutuzumab drives histologic remission in lupus nephritis

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA

At EULAR 2026, investigators are presenting perhaps the most biologically compelling data yet from the REGENCY trial, with evidence that obinutuzumab induces deep intrarenal B-cell depletion alongside markedly higher rates of histological remission.

Read Article
Obinutuzumab drives histologic remission in lupus nephritis At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/13HY1qIDcj
Dr. John Cush RheumNow ( View Tweet)
Three Abstracts That May Shape the Future of RA Treatment Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an https://t.co/CaMSHlkbFD
Dr. John Cush RheumNow ( View Tweet)
SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF

Links:

Dr. John Cush RheumNow ( View Tweet)
#TYK2i #deucravacitinib #RCT in #SLE LTE of #PAISLEY #RCT PERSISTENT #LLDAS &#DORIS #remission over 3 more yrs post 1 yr RCT BUT ++dropouts #POS0695 #EULAR2026 @RheumNow https://t.co/vtrMYrFmJ9

Links:

Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 Please find my video on deep tissue depletion and associated histological remission following treatment with Obinutuzumab in #lupus nephritis @RheumNow https://t.co/V9CNdPsLcV https://t.co/WLVFyaSSUE

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
This study evaluated the risk of flares after sustained drug-free rem in SLE. % of pts w/ reported flares w/n yrs in rem: 48.6% at 2yrs 42.3% at 3yrs 35.2% at 5 yrs Mucocut, msk, renal & immuno - ⬆️affected domain Reassess pts regularly. POS1354 @RheumNow #EULAR2026 https://t.co/DG0yNOW1nh

Links:

sheila RHEUMarampa ( View Tweet)
#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow https://t.co/9COyXbghkl

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Updated SLR on D2T #RA (131 studies): JAKi maintain ACR20 even after 2-3 prior bDMARDs, with UPA outperforming ABA in head-to-head. But evidence on non-pharmacologic strategies in D2T RA remains nearly absent. Clear gap for future trials. @RheumNow #EULAR2026 POS1246

Jiha Lee JihaRheum ( View Tweet)

SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
Dr. John Cush RheumNow ( View Tweet)
#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort: -enriched in Black patients -poor response to B-cell depletion inc. Obi -non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab -High ferritin = flare @RheumNow https://t.co/3uDMigY8i2

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 LB0008 Phase 3 RCT in China of pts with high urate (SUA) & 2 gout flares within last year (N=142), HR091506, an extended formulation release of Febuxostat to prolong response was superior to Febuxostat at WK36. Unclear if will proceed to regulatory submission @RheumNow https://t.co/9lcVEzcxc1

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission? Data from 194 patients from the SELECT-AXIS2 RCT: ▶️ Remission maintained in 1/4 at48 weeks POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×